BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

Volver

Resultados 39 resultados LastUpdate Última actualización 17/12/2018 [16:31:00] pdf PDF




Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 2 nextPage   Mostrar por página


ASSESSMENT OF INTESTINAL BARRIER FUNCTION TO IMPROVE TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: EP3411120A1 12/12/2018

Solicitante:
MAXIMUS DIAGNOSTIC TECH LLC [US]

Resumen de: WO2017136511A1

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1- phosphate receptor agonist agent.



traducir


 

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018346576A1 06/12/2018

Solicitante:
GENENTECH INC [US]

Resumen de: US2018346576A1

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.



traducir


 

DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL INFLAMMATION

NºPublicación: WO2018209318A2 15/11/2018

Solicitante:
BAYLOR COLLEGE MEDICINE [US]

Resumen de: WO2018209318A2

Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.



traducir


 

METHODS OF DETECTING MARKERS FOR INFLAMMATORY CONDITIONS AND FOOD SENSITIVITY IN COMPANION ANIMALS

NºPublicación: US2018328947A1 15/11/2018

Solicitante:
VETICA LABS INC [US]

Resumen de: US2018328947A1

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.



traducir


 

PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME

NºPublicación: US2018321259A1 08/11/2018

Solicitante:
NESTEC SA [CH]

Resumen de: US2018321259A1

The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.



traducir


 

METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018320222A1 08/11/2018

Solicitante:
UNIV OTTAWA [CA]

Resumen de: US2018320222A1

There is provided methods and compositions to diagnose, classify and treat inflammatory bowel disease including ulcerative colitis and Crohn's disease by measuring the levels of certain bacterial taxa and proteins collected from the gut.



traducir


 

NOVEL PSMA-SPECIFIC BINDING PROTEINS

NºPublicación: US2018318451A1 08/11/2018

Solicitante:
TECHNISCHE UNIV MUENCHEN [DE]
BIOTECHNOLOGICKY USTAV AV CR V V I [CZ]

Resumen de: US2018318451A1

The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.



traducir


 

STOOL COLLECTION, CONTAINMENT, AND SPECIMEN DISBURSEMENT SYSTEM

NºPublicación: US2018317892A1 08/11/2018

Solicitante:
CATLIN GEORGE [US]

Resumen de: US2018317892A1

The invention relates to devices for collection, containment, storage and distribution of human stool samples for use in diagnostics related to infectious disease, IBD (Inflammatory Bowel Disease), IBS (Inflammatory Bowel Syndrome) and other disease states or clinical conditions.



traducir


 

Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals

NºPublicación: AU2016349703A1 01/11/2018

Solicitante:
VETICA LABS INC

Resumen de: AU2016349703A1

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), in companion animals, e.g., dogs or cats. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.



traducir


 

METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018305459A1 25/10/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2018305459A1

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.



traducir


 

METHODS OF DETECTING MARKERS FOR INFLAMMATORY CONDITIONS AND FOOD SENSITIVITY IN COMPANION ANIMALS

NºPublicación: US2018306809A1 25/10/2018

Solicitante:
VETICA LABS INC [US]

Resumen de: US2018306809A1

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.



traducir


 

METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2018195328A1 25/10/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2018195328A1

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.



traducir


 

METHODS OF TREATING AND DIAGNOSING IBD ASSOCIATED WITH R. GNAVUS AND/OR R. GNAVUS GROUP IBD COLONIZATION

NºPublicación: WO2018195448A1 25/10/2018

Solicitante:
BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]
HALL ANDREW BRANTLEY [US]
XAVIER RAMNIK [US]
HUTTENHOWER CURTIS [US]
YASSOUR MORAN [US]
VLAMAKIS HERA [US]

Resumen de: WO2018195448A1

This application provides for methods of treatment for IBD, especially in subjects who have R. gnavus species or R. gnavus group IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.



traducir


 

MODULATION OF EPITHELIAL CELL DIFFERENTIATION, MAINTENANCE AND/OR FUNCTION THROUGH T CELL ACTION, AND MARKERS AND METHODS OF USE THEREOF

NºPublicación: WO2018191558A1 18/10/2018

Solicitante:
BROAD INST INC [US]
MASSACHUSETTS INSTITUTE OF TECH [US]
MASSACHUSETTS GEN HOSPITAL [US]
RAJAGOPAL JAYARAJ [US]
REGEV AVIV [US]
BITON MOSHE [US]
HABER ADAM [US]
MONTORO DANIEL [US]
XAVIER RAMNIK [US]

Resumen de: WO2018191558A1

An atlas of intestinal epithelial cells, intestinal epithelial stem cells and intestinal immune cells identifies new cell populations, markers, networks, and responses to stimuli. Intestinal epithelial cell sub-types are also found in the trachea. Accordingly, disclosed are methods of modulating epithelial cell differentiation, maintenance and/or function, related methods for the treatment of disease, including IBD and asthma. Also disclosed are methods and kits for identifying cell types, their differentiation, homeostasis and activation.



traducir


 

Screening and culture method

NºPublicación: GB2561319A 10/10/2018

Solicitante:
OTAKARO PATHWAYS LTD [NZ]

Resumen de: GB2561319A

Methods of culturing and detecting a biomarker which may be associated with autoimmune diseases, in particular inflammatory bowel disease and Crohn's disease; also a screening method for substances suitable for the treatment of inflammatory bowel disease including Crohn's disease; the method including culturing a biomarker in a culture media which includes a culture broth, OADC, PANTA and Mycobactin J.



traducir


 

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2018175913A1 27/09/2018

Solicitante:
MEHARRY MEDICAL COLLEGE [US]

Resumen de: WO2018175913A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.



traducir


 

MARKERS FOR INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018275142A1 27/09/2018

Solicitante:
UNIV OTTAWA [CA]

Resumen de: US2018275142A1

There is provided protein biomarkers and methods for their use in diagnosing and treating Inflammatory Bowel Disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) as well as methods for assessing the severity of the diseases.



traducir


 

Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis

NºPublicación: AU2017234659A1 20/09/2018

Solicitante:
YACYSHYN BRUCE
YACYSHYN MARY

Resumen de: AU2017234659A1

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.



traducir


 

POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS

NºPublicación: WO2018169818A1 20/09/2018

Solicitante:
WANG XIAODONG [US]

Resumen de: WO2018169818A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.



traducir


 

Способ диагностики тяжести течения синдрома раздраженного кишечника

NºPublicación: RU2017108693A 17/09/2018

Solicitante:
\u0413\u043E\u0441\u0443\u0434\u0430\u0440\u0441\u0442\u0432\u0435\u043D\u043D\u043E\u0435 \u0431\u044E\u0434\u0436\u0435\u0442\u043D\u043E\u0435 \u0443\u0447\u0440\u0435\u0436\u0434\u0435\u043D\u0438\u0435 \u0437\u0434\u0440\u0430\u0432\u043E\u043E\u0445\u0440\u0430\u043D\u0435\u043D\u0438\u044F \u0433\u043E\u0440\u043E\u0434\u0430 \u041C\u043E\u0441\u043A\u0432\u044B \u041C\u043E\u0441\u043A\u043E\u0432\u0441\u043A\u0438\u0439 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0439 \u043D\u0430\u0443\u0447\u043D\u043E-\u043F\u0440\u0430\u043A\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0439 \u0446\u0435\u043D\u0442\u0440 \u0414\u0435\u043F\u0430\u0440\u0442\u0430\u043C\u0435\u043D\u0442\u0430 \u0437\u0434\u0440\u0430\u0432\u043E\u043E\u0445\u0440\u0430\u043D\u0435\u043D\u0438\u044F \u0433\u043E\u0440\u043E\u0434\u0430 \u041C\u043E\u0441\u043A\u0432\u044B

 

POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS

NºPublicación: US2018258065A1 13/09/2018

Solicitante:
WANG XIAODONG [US]
ZHONG HUA [US]

Resumen de: US2018258065A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.



traducir


 

PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS

NºPublicación: US2018252728A1 06/09/2018

Solicitante:
AMGEN INC [US]
MEDIMMUNE LLC [US]

Resumen de: US2018252728A1

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.



traducir


 

HOST DNA AS A BIOMARKER OF CROHN'S DISEASE

NºPublicación: US2018251844A1 06/09/2018

Solicitante:
ENTEROME [FR]

Resumen de: US2018251844A1

The invention relates to methods of analysing a sample from a subject having or suspected of having Crohn's disease for the abundance of the subject's nucleic acid (e.g., DNA) in the sample. The invention also relates to methods for measuring abundance of nucleic acid (e.g., DNA) in stool from a human subject having or suspected of having Crohn's Disease (CD). In various embodiments, an in vitro method includes analysing the relative abundance of the host (human) DNA in said sample of stool or nucleic acid extracted or isolated from a stool sample from the host (human); determining the relative abundance of the host (human's) DNA in the sample; and associating the abundance of the host (human) DNA with the host (human) providing the stool sample, or the host (human) providing the stool sample from which the nucleic acid was extracted.



traducir


 

GENE SIGNATURES OF INFLAMMATORY DISORDERS THAT RELATE TO THE LIVER

NºPublicación: US2018251819A1 06/09/2018

Solicitante:
ENTEROME [FR]
NSTITUT NATIONAL DE LA RECH AGRONOMIQUE [FR]

Resumen de: US2018251819A1

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.



traducir


 

COMPOSITIONS AND METHODS FOR DIAGNOSING COLON DISORDERS

Nº publicación: US2018251820A1 06/09/2018

Solicitante:
GEORGE MASON RES FOUNDATION INC [US]
RUSH UNIV [US]

Resumen de: US2018251820A1

The present invention relates to methods and compositions for diagnosing, monitoring, prognosticating, analyzing, etc., polymicrobial diseases. The present invention also relates to the microbial community present in the digestive tract and lumen in normal subjects, and subjects with digestive tract diseases, especially diseases of the colon, such as inflammatory bowel disease, including ulcerative colitis, Crohn's syndrome, and pouchitis. The present invention especially relates to compositions and methods for diagnosing and prognosticating the mentioned diseases and conditions, e.g., to determine the presence of the disease in a subject, to determine a therapeutic regimen, to determine the onset of active disease, to determine the predisposition to the disease, etc.


traducir



 

Página1 de 2 nextPage Mostrar por página

Volver